On Monday, Shares of Scorpio Tankers Inc. (NYSE:STNG), subtract -0.92% and closed at $4.31 in the last trading session. STNG stock opened its last trade at $4.38 and after floating in a range of $4.25 to $4.39. The company’s Market capitalization is $744.08 million with the total Outstanding Shares of 172.38 million. During the 52-week trading session the minimum price at which share price traded, registered at $4.05 and reached to max level of $9.76. Scorpio Tankers Inc., together with its auxiliaries, engages in the seaborne transportation of refined petroleum products and crude oil worldwide. As of March 17, 2016, it owned 78 tankers comprising 18 LR2 tankers, 14 Handymax tankers, and 46 MR tankers with an average age of about 1.5 years; and 11 time chartered-in tankers, counting 3 LR2, 1 LR1, 4 MR, and 3 Handymax tankers.
Endo International plc – Ordinary Shares (NASDAQ:ENDP), dropped -2.97% and closed at $19.27 in the last trading session. ENDP stock opened its last trade at $19.79 and after floating in a range of $19.15 to $20.04. The company’s Market capitalization is $4.42 Billion with the total Outstanding Shares of 222.77 million. During the 52-week trading session the minimum price at which share price traded, registered at $12.56 and reached to max level of $69.33. Endo International plc develops, manufactures, and distributes pharmaceutical products and devices worldwide. Its U.S. Branded Pharmaceuticals segment offers chronic pain administration products, such as BELBUCA, OPANA ER, and Percocet; Lidoderm for opioid analgesics; and Voltaren gel for osteoarthritis pain, in addition to XIAFLEX for treating Peyronies and Dupuytrens contracture diseases. This segment also provides Supprelin LA for central precocious puberty treatment; testosterone replacement therapies, such as Aveed and TESTOPEL, in addition to Fortesta and Testim gels; Frova and Sumavel DosePro for migraine headaches; Valstar, a sterile solution for intravesical instillation of valrubicin; and Vantas for the palliative treatment of prostate cancer. The companys U.S. Generic Pharmaceuticals segment provides tablets, capsules, powders, injectables, liquids, nasal sprays, ophthalmics, and transdermal patches for pain administration, urology, central nervous system disorders, immunosuppression, oncology, womens health, and cardiovascular disease markets. Its International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas, counting attention deficit hyperactivity disorder, pain, womens health, and oncology; generic, branded generic, and over-the-counter products in the areas of dermatology and anti-infectives; injectables for the treatment of pain, anti-infectives, cardiovascular, and other therapeutics areas; and healthcare services, products, and solutions to hospitals, pharmacies, and practitioners, in addition to for government healthcare programs. The company also provides Monarc subfascial hammock to treat female stress urinary incontinence; and Elevate transvaginal pelvic floor repair system for the treatment of pelvic organ prolapse.